 melanoma tumor vaccin five-year follow-up mani year variou melanoma vaccin uniqu melanoma vaccin subcellular tumor homogen adjuv vaccin stage stage II melanoma patient year surviv rate sixty-four stage male stage surviv rate differ lymph node dissect thirty-six stage II male stage II femal surviv rate stage II patient posit node posit node posit node surviv rate publish seri histor control signific differ stage II patient posit node posit node signific increas surviv stage II patient high risk recurr tumor homogen vaccin vaccin warrant analysi develop use phase iii clinic trial